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Approximately 25% of colorectal cancer patients in sub-Saharan Africa are younger than 40
years, and hereditary factors may contribute. We investigated the frequency and patterns of
inherited colorectal cancer among black Zimbabweans.
Methods
A population-based cross-sectional study of ninety individuals with a new diagnosis of colo-
rectal cancer was carried out in Harare, Zimbabwe between November 2012 and December
2015. Phenotypic data was obtained using interviewer administered questionnaires, and
reviewing clinical and pathology data. Cases were screened for mismatch repair deficiency
by immunohistochemistry and/or microsatellite instability testing, and for MLH1, MSH2 and
EPCAM deletions using multiplex ligation-dependent probe amplification. Next generation
sequencing using a 16-gene panel was performed for cases with phenotypic features con-
sistent with familial colorectal cancer. Variants were assessed for pathogenicity using the
mean allele frequency, phenotypic features and searching online databases.
Results
Three Lynch syndrome cases were identified: MSH2 c.2634G>A pathogenic mutation, c.
(1896+1_1897–1)_(*193_?)del , and one fulfilling the Amsterdam criteria, with MLH1 and
PMS2 deficiency, but no identifiable pathogenic mutation. Two other cases had a strong
family history of cancers, but the exact syndrome was not identified. The prevalence of
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Lynch syndrome was 3�3% (95% CI 0�7–9�4), and that of familial colorectal cancer was
5�6% (95% CI, 1�8–12�5).
Conclusions
Identifying cases of inherited colorectal cancer in sub-Saharan Africa is feasible, and our
findings can inform screening guidelines appropriate to this setting.
Introduction
The incidence of colorectal cancer is gradually rising in some countries in sub-Saharan Africa,
including Kenya, Nigeria, and Zimbabwe.[1] In Zimbabwe, the incidence of colorectal cancer
has been rising steadily, averaging 4% annually since 1991.[2] This rising incidence is probably
due to improvements in diagnosis, and to changes in the prevalence of known risk factors.[1]
These factors include urbanisation, diabetes mellitus, schistosomiasis, and shifts from tradi-
tional dietary patterns, which are associated with colorectal cancer among black Zimbab-
weans.[3, 4] There is circumstantial evidence that familial predisposition plays a prominent
role in colorectal cancer across Africa, but the degree and patterns have not been
characterised.
Approximately 1 in 4 individuals with colorectal cancer in sub-Saharan Africa is under the
age of 40 years.[1] In general, young people with colorectal cancer are more likely to have a
pathogenic germline mutation.[5, 6] Thus, it has been hypothesised that the frequency of
hereditary colorectal cancers, particularly Lynch syndrome, is high in sub-Saharan Africa.[7]
This is supported by the high frequency of histological features associated with Lynch syn-
drome (mucinous and signet ring cell morphology), and of mismatch repair protein deficiency
in colorectal cancers in this region.[7–9] The earlier age of onset of colorectal cancer among
African-Americans also provides additional, indirect evidence of an intrinsic genetic predispo-
sition among people of African ancestry.[10]
While this theory is plausible, there is lack of solid supporting evidence. Previous studies
reported the frequency of mismatch repair deficiency in archived tissue, without further, com-
prehensive analysis.[7, 9] Phenotypic data, in particular family history, was often inadequate,
and the causative mutations were not characterised. The increasing availability of next genera-
tion sequencing platforms in a few academic centres in Africa, provides an opportunity to
bridge this gap. Therefore, we investigated the frequency and mutation spectrum of hereditary
colorectal cancers in a prospective, population-based cohort of black Zimbabwean patients.
Materials and methods
Study population
Newly diagnosed cases of colorectal cancer were prospectively recruited in Harare, Zimbabwe,
between November 2012 and December 2014, as previously described.[3] They were recruited
from hospitals, clinicians, and pathology laboratories in both public and private practice in
Harare. The cases, who mainly came from the northern two thirds of Zimbabwe, were repre-
sentative of the overall black population. Pathology specimens from this region are processed
at one of four laboratories in Harare, allowing accurate case tracing. A network of pathologists,
and clinicians was consequently established for this purpose. Ethical approval was obtained
from the institutional review boards of the University of Zimbabwe, the University of Cape
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Data collection
The participants were recruited within six months of a histologically confirmed diagnosis of
colorectal cancer. After informed consent, phenotypic data was obtained using interviewer-
administered questionnaires covering demographic variables, and detailed personal, and fam-
ily history of cancer. Data on tumour pathology (location, morphology, grading and presence
of synchronous neoplasia) were obtained from pathology and endoscopic reports.
Venous blood was drawn for germline DNA, and paraffin-embedded tumour blocks were
obtained from pathology laboratories. Initial screening for Lynch syndrome was performed
using immunohistochemistry and/or microsatellite instability testing. Immunohistochemistry
was used as a parallel method of assessing mismatch repair deficiency, and to possibly indicate
the mutated gene. Screening for germline MLH1, MSH2 and EPCAM deletions was performed
regardless of the mismatch repair status using multiplex ligation-dependent probe amplifica-
tion (MLPA). A phenotype-guided strategy was then used to select cases for next generation
germline sequencing. The phenotypic features considered included family history of cancer
and colorectal cancer, prior history of cancer, age< 40 years, mucinous or signet ring mor-
phology, presence of synchronous tumours, polyposis, mismatch repair-protein status and
BRAF V600E result.
Screening for Lynch syndrome
Microsatellite instability (MSI) testing was performed on paired germline and tumour DNA
samples using the Promega MSI Analysis System version 1.2 (Promega Corporation, Madison,
Wisconsin, United States). Germline DNA was obtained from peripheral blood, or normal tis-
sue on tumour slides using standard techniques. Fluorescently-labelled primers were used for
co-amplification of seven markers; five mononucleotide (BAT-25, BAT-26, NR-21, NR-24 and
MONO-27), and two pentanucleotide (Penta C and Penta D) repeat markers. The PCR prod-
ucts were separated by capillary electrophoresis (Applied Biosystems 3130 Genetic Analyzer),
and the output analysed with GeneMapper version 4.0 software (Applied Biosystems; Foster
City, CA, USA). The results were interpreted as follows: MSI at 2 or more mononucleotide
loci, MSI-high (MSI-H) ; MSI at a single mononucleotide locus, MSI-Low (MSI-L) and no
instability at any of the loci, microsatellite stable (MSS).
Immunohistochemistry was performed using anti-MSH2 and anti-PMS2 mouse monoclo-
nal antibodies (Cell Marque; Rocklin, California, USA), and anti-MLH1 and anti-MSH6
mouse monoclonal antibodies (Ventana Medical Systems; Tucson, Arizona, USA) on forma-
lin-fixed, paraffin-embedded tissue sections. Tissue sections with normal colonic mucosa adja-
cent to the tumour were selected for immunohistochemistry. The normal areas acted as
internal positive controls, while external control positive controls were also included (normal
colonic mucosa). A Ventana Benchmark XT autostainer and the Opti-view detection system
(Ventana Medical Systems; Tucson, Arizona, USA) were used, following the manufacturers’
protocol. The stained slides were interpreted by an experienced pathologist (DG).
All cases that were MLH1 protein deficient, with a high level of microsatellite instability
(MSI-H) were sequenced for the BRAF V600E mutation. The following primers were used:
Forward, 5'-CTACTGTTTTCCTTTACTTACTACACCTCAGA-3'; and reverse, 5'-ATCCA
GACAACTGTTCAAACTGATG-3’. Sequencing was performed using BigDye terminator v3.1
cycle sequencing kit (Thermofisher Scientific, Wilmington, USA) following standard
protocols.
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MLPA for MLH1, MSH2 and EPCAM germline deletions was performed using the SALSA
MLPA kit (MRC-Holland, Amsterdam, Netherlands) according to the manufacturer’s proto-
col. Briefly, germline DNA was denatured, followed by hybridisation with MLPA probes, liga-
tion and amplification. The amplified products were visualised using capillary electrophoresis,
and the output analysed using the Coffalyser.Net software (https://www.mlpa.com).
Next generation sequencing using a multigene panel
Next generation sequencing of germline DNA from peripheral blood was performed on
selected cases using a custom panel of 16 colorectal cancer genes (MUTYH, EPCAM, MSH2,
MSH6, MLH1, PMS2, FBX011, APC, BMPRIA, KLLN, PTEN, POLE, POLD1, TP53, SMAD4,
and STK11). DNA quality assurance was performed using agarose gel electrophoresis and
spectrophotometry (Nano-Drop 1000) (ThermoFisher Scientific, Wilmington, USA). DNA
quantification was performed using real time PCR with the RNase P assay. DNA dilutions and
library preparation were performed on the Ion Chef using the DL8 kit (ThermoFisher Scien-
tific, Wilmington, USA), followed by template preparation and sequencing on the Ion Chef
personal genome machine as per manufacturer’s protocol. The output was analysed using the
Ion Reporter ((ThermoFisher Scientific, Wilmington, USA). Variants with a mean allele
frequency< 0.01 were considered potentially pathogenic, and cross-referenced with online
databases, including Clin-Var (https://www.ncbi.nlm.nih.gov/clinvar/), InSiGHT (https://
www.insight-group.org/variants/databases/), and LOVD (http://www.lovd.nl/3.0/home). Phe-
notypic characteristics, particularly family history, immunohistochemistry and MSI status
were considered in evaluating pathogenicity.
Statistical methods
Descriptive statistics including percentages (with 95% confidence intervals), mean (with stan-
dard deviations), and median (with inter-quartile range) were used to summarise data. The sta-
tistical analysis was performed using Stata MP Version 12.01 (College Station, Texas, USA).
Results
A total of 101 black Zimbabwean patients with newly diagnosed colorectal cancer were
recruited in Harare, between November 2012 and December 2015. Complete analysis for
hereditary colorectal syndromes was performed in 90 cases (Fig 1). The mean age for these
cases was 52�3 years, with 20 (22%) under 40 years of age (Table 1). Sixty-eight cases (75�6%),
had tumours distal to the splenic flexure (i.e. left-sided), including 49 (54%), that were in the
rectum. There were 14 (16%) mucinous adenocarcinomas and 8 (9%) signet ring cell carcino-
mas. One case fulfilled the Amsterdam II criteria for Lynch syndrome.
The frequency and patterns of mismatch repair deficiency
Mismatch repair status was available in 89 cases; 53 from MSI and immunohistochemistry,
and 36 from immunohistochemistry alone (Table 2). There were no mismatch repair results in
one case, but he was selected for next generation sequencing because of ‘young age’, and
abnormal MLPA result. The MSI status in the 53 cases were as follows: MSS, 44 (83%); MSI-H,
6 (11�3%) and MSI-L), 3 (5�7%). Mismatch repair protein deficiency on immunohistochemis-
try was present in 6 (6�7%) of the 89 cases. Four were MLH1 and PMS2 deficient (and BRAF
V600E negative), one was MSH2 and MSH6 deficient, and one had isolated MSH2 deficiency.
In the 53 cases where both immunohistochemistry and MSI results were available, there was
concordance in all, but one case (98�1% concordance) (Table 2).
Hereditary colorectal cancers in Zimbabwe
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Fig 1. Study flowchart describing the laboratory process for evaluating cases for inherited colorectal cancer (-ve–
negative).
https://doi.org/10.1371/journal.pone.0224023.g001
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The frequency and patterns of pathogenic germline variants identified by
next generation sequencing
Next generation sequencing was performed in 16 cases summarised in Table 3. Two cases had
a history of colorectal cancer in 1st degree relatives, one of whom met the Amsterdam criteria
for Lynch syndrome. One case of Lynch syndrome was identified on next generation sequenc-
ing, a 48-year-old woman with a rectal tumour, and a pathogenic variant in MSH2,
(NM_000251.2, c.2634G>A, p.Glu878 = ), but no obvious family history of colorectal cancer
(Table 4). Immunohistochemistry was consistent with a pathogenic variant, with loss of
expression of MSH2. This variant has been shown to be pathogenic in a Spanish population,
and causes splicing aberration leading to a truncated protein.[13, 14] There were no germline
pathogenic variants identified in any of the 16 genes in the other 15 cases.
The frequency and patterns of MLH1, MSH2 and EPCAM deletions
MLPA for MLH1, MSH2 and EPCAM germline deletions was successful in 66 cases. One likely
pathogenic deletion was identified, an MLH1 Ex 17–19 deletion, i.e., NM-000249.3, MLH1 c.
(1896+1_1897–1)_(�193_?)del , in a 41-year-old man with a rectal adenocarcinoma. The
tumour was mismatch repair protein proficient and there was a history of unspecified
Table 1. Demographic and clinical characteristics in the ninety cases.
Variable Frequency
n (%) or Mean (SD)
Mean age (Years) 52�3(14�9)
Age Category (Years)





Proximal colon 18 (20�0)
Distal colon 19 (21�1)
Rectum 49(54�5)
Synchronous hepatic flexure and rectum 1(1�1)




Signet ring cell carcinoma 8(8�9)
Cancer in 1st degree relatives 18(20)
Colorectal cancer in 1st degree relatives 2
Personal history of cancer 3 (3�3)
Amsterdam II Criteria†[11] 1
At least one Bethesda criterion present‡[12] 45 (50)
†3 or more family members with a Lynch tumour, 2 successive generations, 1 or more Lynch related tumour before
the age of 50 years.
‡CRC at < 50 years, synchronous or metachronous CRC or other Lynch tumours, MSI-H histology at age < 60
years, appropriate family history.
https://doi.org/10.1371/journal.pone.0224023.t001
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intestinal cancer in his brother, and maternal aunt (Table 4). Deletions were also identified in
two other cases, an MSH2 ex 11 deletion, and an MSH2 ex 6 deletion. These were small and
considered likely false positive. This assertion was supported by the unremarkable phenotype
in both cases.
Summary of inherited colorectal cancer syndromes in the cohort
There were 3 Lynch syndrome cases (Table 4) giving a prevalence of 3�3% (95% CI, 0�7–9�4).
These were as follows: MSH2, c.2634G>A mutation, MLH1 c.(1896+1_1897–1)_(�193_?)del ,
and the case fulfilling the Amsterdam criteria. The individual fulfilling the Amsterdam criteria
was a 34-year-old woman with a well-differentiated adenocarcinoma in the transverse colon,
and a history of colorectal cancers in both 1st and 2nd degree relatives (Table 4 and Fig 2). The
tumour was MSI-H, MLH1 and PMS2 deficient, and negative for BRAF V600E, but no patho-
genic mutation was identified on next generation sequencing. The case fulfilled the Amster-
dam II criteria, making a double somatic mutation as an explanation for the mismatch repair
deficiency unlikely. There were two other cases with a family history highly suggestive of
inherited colorectal cancer syndromes, but no mutations were identified (Table 4). They were
both mismatch repair protein proficient, suggesting syndromes other than Lynch. A variant of
unknown significance was identified in one of these individuals, a 54-year-old woman with a
previous history of breast cancer. This was a missense mutation in MSH6 (NM_000179.2;
c.124C>T ; p.Pro42Ser). [15]
Therefore, it can be reasonably concluded that, the minimum prevalence of inherited colo-
rectal cancer syndromes in our population ranges from 3�3% (95% CI 0�7–9�4) to 5�6% (95%
CI, 1�8–12�5).
Discussion
This study aimed to establish the role of the established hereditary syndromes in colorectal
cancer in sub-Saharan Africa, where the frequency of early-onset disease is disproportionately
high. We concluded that up to 1 in 18 patients with colorectal cancer have an underlying high
penetrance genetic predisposition. However, we found no evidence to support the hypothesis
that the high frequency of early onset colorectal cancer in our population is associated with fre-
quent germline mutations in the established high penetrance genes, particularly Lynch syn-
drome. This correlates with the axiom that, while most hereditary colorectal cancers occur at
an early age, most early onset colorectal cancers are not hereditary.[16]
Table 2. Mismatch repair status in 89 cases of colorectal cancer and the likelihood of Lynch syndrome.
MSI status (n) Protein expression Interpretation
MLH1 MSH2 MSH6 PMS2
MSS (44) + + + + Not Lynch
MSI-H (1) + + + + Discordant result
MSI- H (1) + - - + Lynch likely
MSI-H (4) - + + - Lynch or sporadic
MSI-L (3) + + + + Not Lynch
Unknown (35) † + + + + Not Lynch
Unknown (1) + - + + Likely Lynch
†Incomplete MSI testing in 31, no normal tissue in 4.
https://doi.org/10.1371/journal.pone.0224023.t002
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In our study, 3�3–5�6% of patients had hereditary colorectal cancers, which is similar to esti-
mates from the traditional high incidence countries.[17] The prevalence of Lynch syndrome
was also within the global range of 2–4%.[18] There were no germline pathogenic variants in
the other known colorectal cancer susceptibility genes sequenced using the multi-gene panel.
Table 3. Characteristics of the 16 cases selected for next generation sequencing using a multi-gene colorectal can-
cer panel.










Synchronous (hepatic and rectal) 1





Any Lynch cancer 3
Colorectal cancer 2
Breast and duodenal cancers 1




Signet ring cell carcinoma 3
Other pathological characteristics
Synchronous tumours 1







MLH1 and PMS2 4
MSH2 and MSH6 1
MSH2 alone 1
https://doi.org/10.1371/journal.pone.0224023.t003
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Thus, although there is a high rate of early onset colorectal cancer in our population, we found
no convincing evidence of a correspondingly high frequency of familial cases. In contrast,
recent evidence suggests that the prevalence of germline pathogenic variants in colorectal can-
cer susceptibility genes among young people is underestimated.[5, 19] Despite this, we are rea-
sonably certain that the majority of the early onset colorectal cancers in our study were
sporadic. It is possible that there are contributory environmental factors unique to this patient
Table 4. Confirmed and probable cases of inherited colorectal cancer syndromes in the cohort.
Age
(Sex)







Father, suspected CRC, 40s. Sister colon, 42. Two aunts, colon,






41(M) Rectum Brother and maternal aunt: unclear intestinal tumours MMR proficient MLH1 c.(1896+1_1897–1)_
(�193_?)del
?
48(F) Rectum Unknown MSH2 deficient MSH2 c.2634G>A p.Glu878 =
Other
54(F) Rectum Proband previous breast cancer, Sister–breast, 44 years. Father-
duodenal. Mother- lung adenocarcinoma, non-smoker
Proficient ? Unidentified ?
35(F) Rectum Mother–CRC 50 years Proficient ? Unidentified ?
https://doi.org/10.1371/journal.pone.0224023.t004
Fig 2. Pedigree analysis in a Lynch syndrome case meeting the Amsterdam II criteria, but with an unidentified MLH1 or PMS2 mutation.
https://doi.org/10.1371/journal.pone.0224023.g002
Hereditary colorectal cancers in Zimbabwe
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population; we have previously demonstrated a relationship between colorectal cancer and
prior schistosomiasis.[3]
Our findings have implications for screening for Lynch syndrome in clinical practice in low
resource settings. International guidelines recommend universal screening for mismatch
repair deficiency of all colorectal cancers occurring below the age of 70 years.[11, 20] Universal
screening is particularly suited to sub-Saharan Africa, where implementing phenotypic
approach has unique challenges. The family history of cancers is masked by the high burden of
infectious diseases, low life expectancy, low diagnostic rates and lack of population level
knowledge of familial colorectal cancer.[21, 22] However, universal screening is impractical in
sub-Saharan Africa, given the competing priorities for resources. While tools such as the
Bethesda guidelines may be utilised, they are likely to have a low positive predictive value as a
high proportion of colorectal cancer patients meet the criteria. A viable option for sub-Saharan
Africa would be to lower the cut-off age for universal screening to 50 years–the Lynch syn-
drome cases identified in our study were all younger than 50 years. Our study also reaffirms
the role of immunohistochemistry in screening for Lynch syndrome in clinical practice, and
this is a low-cost option for low and medium income countries.[23]
In contrast, our findings suggest that BRAF V600E screening may not be useful in sub-
Saharan Africa. The 3 cases that were MSI-H, MLH1 deficient and BRAF V600E negative were
all found to be sporadic after sequencing. The 4th case had phenotypic features of Lynch syn-
drome, and the BRAF V600E result would have been inconsequential in clinical practice. A
retrospective study in Ghana found no BRAF mutations in 88 unselected cases, despite a high
proportion of MSI-H tumours.[9] Taken together, this suggests that BRAF mutations are
uncommon in sporadic colorectal cancer in sub-Saharan Africa. The role of BRAF mutation,
or MLH1 hypermethylation promoter testing in African populations require further confirma-
tion in a hypothesis driven study. An analogy can be made drawn with the Chinese population,
where a low frequency of BRAF mutations was noted, and analysis for MLH1 hypermethyla-
tion was shown to be more efficient for triaging cases for further genetic analysis.[24] We did
not evaluate specifically for MLH1 hypermethylation in our study because the number of cases
was too small to justify the added cost. Moreover, next generation sequencing was performed
in all the cases that may have required MLH1 hypermethylation analysis.
Our study had limitations which must be taken into account when interpreting the find-
ings. First, we used a phenotype guided strategy to select cases for sequencing to reduce costs.
Consequently, we may have missed some inherited colorectal cancer syndromes, and our find-
ings must be regarded as the minimum possible prevalence. However, it is unlikely that we
underestimated the prevalence of Lynch syndrome, which we screened for comprehensively
using a combination of immunohistochemistry, MSI testing, MLPA, and next generation
sequencing. Second, it is possible that we missed pathogenic germline variants in moderate
penetrance colorectal cancer genes such as ATM, SMAD3, or high penetrance syndromes pri-
marily associated with other cancers such as BRCA1 and BRCA2, which were not part of our
panel. For example, one of our participants, who had a prior history of breast cancer, and a
family history of breast and gastrointestinal cancers could have a BRCA 1 or 2 mutation. It is
increasingly recognised that BRCA 1 or 2 mutations are associated with colorectal cancer,
although this may not be causal.[25] Third, not all early-onset cases were sequenced in our
study, thus the findings in this sub-group must be considered exploratory. Fourth, case series
of this nature may be subject to referral bias, particularly of young individuals and those with a
positive family history of colorectal cancer. Our recruitment strategy minimised this by target-
ing all colorectal cancer patients seen at different levels of care within the catchment area. The
similarity in the age distribution of the participants in our study, and the pattern described
previously in sub-Saharan Africa is reassuring.[1] Finally, access to healthcare in Zimbabwe is
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uneven, and often affected by cultural and economic factors, and a significant proportion of
gastrointestinal cancers are probably not identified. Thus, it is likely that our study missed
some colorectal cancer cases in the study population.
However, this is the first prospective study to comprehensively evaluate the contribution,
and patterns of inherited colorectal cancer syndromes in the poorly researched populations of
sub-Saharan Africa. This study had comprehensive phenotypic data, and was based on an
unselected population from both rural and urban areas. Thus, it can be considered representa-
tive of patients with colorectal cancer in sub-Saharan Africa. It forms a solid basis for larger
studies, covering an even wider array of colorectal cancer susceptibility genes, and for context-
specific clinical guideline development. As the immediate next step, it would be reasonable to
consider performing whole exome sequencing for both tumour and germline tissue in individ-
uals under the age of 50 years to more fully explore the involvement of other genes in early
onset of colorectal cancers in our population.
To conclude, at least 1 in 30 patients with colorectal cancer in our population have Lynch
syndrome. Identifying cases of inherited colorectal cancer and instituting screening among
family members can have a quantifiable impact on the incidence in low prevalence countries.
The use of a detailed family history, complemented by screening for Lynch syndrome using
immunohistochemistry should be encouraged in these countries, where genomic technologies
are unavailable in clinical practice. Ultimately, the goal should be to screen all young patients
for Lynch syndrome in these countries using immunohistochemistry, and to intensify research
into the causes of colorectal cancer in this demographic group. Our study demonstrates the
feasibility of next generation sequencing in low- and medium-income countries, and hopefully
these will eventually cascade into clinical practice as the costs continue to fall. Lastly, the
majority of colorectal cancers in young people in Zimbabwe, and probably sub-Saharan Africa
are not due to Lynch syndrome. This provides a unique opportunity for collaborative research
into early onset colorectal cancer, which is an emerging global challenge.
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